Adamis Pharmaceuticals Corporation provided earnings guidance for the first half of 2019, for the first half, the company expects net sales for this division to be approximately $10 million and, by year-end, to total $22 million. If company achieve those goals, it would represent a 45% increase over 2018, and company would expect the division to be net positive for Adamis.